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Abstract 15 
Saikosaponin d (SSd) is an active extract from Radix Bupleuri, the dried root from the plant Bupleurum 16 
falcatum used in China for thousands of years to treat liver diseases. The SSd extract possesses valuable 17 
pharmacological activities including anti-cancer and anti-inflammatory effects, however, the 18 
mechanism underlying the anti-cancer activity of SSd is largely unknown. Here we explored the 19 
mechanism of action of SSd as an anti-cancer agent for liver cancer in two human hepatocellular 20 
carcinoma cell lines. Using MTT and annexin-V-FITC/PI assays, Western blots, 21 
immunohistochemistry, qRT-PCR, luciferase reporter assay, and a JAK2 specific-inhibitor (AG490), 22 
we demonstrated that the anti-tumorigenic effects of SSd acts through the intermediatory p-23 
STAT3/C/EBPβ signaling pathway to suppress cyclooxygenase (COX)-2. SSd effectively inhibited 24 
cell proliferation in a dose-dependent manner. Apoptosis was significantly increased in cells treated 25 
with SSd (2.5 µg/ml-15 µg/ml) with concurrent increase and decrease in pro-and anti-apoptosis 26 
proteins, respectively. COX-2, C/EBPβ, and p-STAT3 were significantly decreased, at both the 27 
translational and transcriptional levels, by SSd treatment. AG490 produced similar inhibitory effects 28 
on STAT3, p-STAT3, C/EBPβ and COX-2. In conclusion, our data suggests that SSd controls liver 29 
cancer proliferation through suppression of the p-STAT3/C/EBPβ signaling pathway inhibiting COX2 30 
expression. These findings further our understanding of the pharmacological action of SSd providing 31 
new information on SSd mechanism of action and shows potential for SSd as a novel therapy for liver 32 
cancer. 33 
 34 
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1 Introduction 36 
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second cancer killer 37 
worldwide (1). Incidence and mortality rates of HCC are most prevalent in Eastern and South-Eastern 38 
Asia (1). HCC is aggressive and has a poor prognosis with an overall ratio of mortality to incidence of 39 
0.95. The majority of HCC patients are diagnosed at an advanced stage when treatment options are 40 
very limited and mostly ineffective. Therefore, new effective therapeutic strategies are needed to 41 
improve long-term survival. Saikosaponin d (SSd) is a natural plant product and has been proposed as 42 
a new efficacious treatment for HCCs patients (2-4).  43 
For thousands of years herbs have been used in traditional Chinese medicine (TCM) to treat various 44 
liver diseases, including cancer (3, 4). Radix Bupleuri is a popular herb that is still used today in about 45 
150 traditional Chinese prescriptions for various clinical conditions including liver diseases in China 46 
(3-5). Radix Bupleuri (Chaihu in Chinese, Saiko in Japanese) is the dried root of the plant Bupleurum 47 
falcatum L (3, 4) and is commonly used as a principal herb in a classic compound herbal formula called 48 
Xiao Chai Hu Tang (XCHT, or Sho-saiko-to in Japanese) to treat hepatocellular carcinoma (6-8). In a 49 
prospective randomized clinical trial, Oka et al convincingly show that XCHT can prevent the 50 
development of HCC in patients with cirrhosis (6). 51 
The phytochemistry, pharmacology and mode of action of the genus Bupleurum (9) and the derivatives 52 
of the dried root, Radix Bupleuri, have been extensively characterized (10). The active saikosaponins 53 
and extracts isolated from Radix Bupleuri and their applications have been recently reviewed (4). SSd 54 
is one of the major active triterpene saponins, a natural molecule extracted from Radix Bupleuri. 55 
Pharmacological benefits of SSd include anti-cancer, anti-inflammatory, antipyretic, antimicrobial, 56 
antiviral, hepato-protective and immunomodulatory effects (4). Since the anti-cancer properties of SSd 57 
were first identified in 1994 (11), anti-proliferation, anti-metastasis, and anti-angiogenesis have been 58 
demonstrated both in vitro (11, 12) and in vivo (2, 6, 13). The in vitro antitumor properties of SSd has 59 
been demonstrated in human hepatoma (11), human hepatocellular cells (14)(SMMC7721, HepG2, 60 
Hep3B, and 2.2.15), lung cancer, A549 cells (15), prostate carcinoma, DU145 cells (16), cervical 61 
carcinoma, Hela cells (17), breast carcinoma, MCF-7 cells (18) and thyroid cancer cells (ARO, 8305C, 62 
and SW1736) (19). Albeit, the exact mechanisms by which SSd exerts its anti-cancer effects are 63 
unclear. 64 
COX-2 is a rate-limiting enzyme in the production of prostaglandins promoted by a variety of factors 65 
including cytokines, growth factors and tumor promoters (20). The overexpression of COX-2 is 66 
observed in many human cancers such as prostate (21), breast (22), lung (23), and liver cancer (24-31). 67 
The importance of the strong association between COX-2 overexpression and HCC has been well 68 
documented (24-32).  Several studies found that COX-2 promoted HCC cell growth, migration and 69 
invasion (26, 29).  In HCC patients, the protein expression of COX-2 correlates well with 70 
differentiation grades, suggesting that abnormal COX-2 expression has an important effect in 71 
hepatocarcinogenesis (31). Recently, in vivo mouse studies demonstrated that overexpression of COX-72 
2 in the liver was sufficient to induce HCC (24). COX-2 overexpression has been shown to promote 73 
tumor initiation and proliferation and inhibit apoptosis by mediating the activation of downstream 74 
oncogenic pathways (33). Thus, the role of COX-2 in the pathogenesis of HCC is relatively well 75 
defined and deregulation of the COX-2 signaling pathway may serve as a basis for designing novel-76 
targeted therapeutic strategies for cancer therapy. What is unclear is the upstream regulatory network 77 
controlling COX-2 expression.  78 
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Our laboratory has played an important role in describing the significance of SSd suppression of COX-79 
2 in HCCs and the SSd’s chemo-preventive effect on liver cancer associating with COX-2 inhibition 80 
(13, 14, 34, 35). In this study we extend these findings to understand the upstream mechanism of COX-81 
2 inhibition by SSd treatment. The transcription factor CCAAT/enhancer binding protein β (C/EBPβ) 82 
is one of the key regulators implicated in COX-2 expression (36). Herein, for the first time, we 83 
presented our latest data demonstrating how SSd acted through the p-STAT3/C/EBPβ signaling 84 
pathway leading to COX-2 suppression and antitumor activity in human HCC cells. This information 85 
will contribute to our new understanding of the mechanisms of action by which SSd contributes to the 86 
treatment and prevention of HCC. 87 
2 Materials and Methods 88 
2.1 Reagents and chemicals 89 
RPMI-1640 medium was purchased from Invitrogen Life Technologies, CA, USA. Fetal bovine serum 90 
(FBS) was supplied by HyClone, UT, USA. Tyrphostin AG490 (a JAK2 kinase inhibitor), dimethyl 91 
sulfoxide (DMSO), and acetic acid were purchased from Sigma (Poole, UK). IL-6 was purchased from 92 
Pepro Tech (NJ, USA). The primary antibodies against total STAT3, COX-2 and β-actin, and 93 
Streptavidin/Peroxidase for immunochemical staining were purchased from BIOS China, and the 94 
antibody against phosphorylated tyrosine705 STAT3 (p-tyr-705 STAT3) was purchased from Cell 95 
Signaling Technology (Massachusetts, USA). The anti-C/EBPβ antibody was purchased from Santa 96 
Cruz (California, USA). Cell culture dishes were purchased from NECU (Denmark). IL-6 was 97 
dissolved in acetic acid to a stock concentration of 1μg/mL, AG490 was dissolved in DMSO to a stock 98 
concentration of 100 mM/L. Both stock solutions were stored at -20 ℃ for further use. For all 99 
experiments, the optimal working concentrations of the tested reagents were prepared by diluting with 100 
RPMI-1640 medium. 101 
2.2 SSd and its preparation 102 
The SSd extract (purity ≥ 95%) from Bupleurum falcatnum was purchased from Sigma (Poole, UK). 103 
For all experiments, a stock solution was prepared by dissolving SSd into DMSO to a concentration of 104 
10 mg/ml and stored at -20℃. The final concentrations of the tested compound were prepared by 105 
diluting the stock solution with DMEM. The final concentration of DMSO was less than 0.1%.  106 
2.3 Cell lines and cell culture  107 
The human hepatocellular carcinoma cell line SMMC-7721 was a kind gift from Professor Chen Wei 108 
(the First Affiliated Hospital of Xi’an Jiaotong University), and the human hepatocellular carcinoma 109 
HepG2 cell line was kindly provided by Urology Institute of Xi’an Jiaotong University. The identity 110 
and authentication of both cell lines used was confirmed by relevant authorized STR profile reports. 111 
Both SMMC-7721 and HepG2 cells were cultured as described previously and have been used 112 
extensively to study liver cancer (14). 113 
2.4 Cell proliferation assay 114 
The effect of SSd on cell proliferation was tested using the MTT assay. The cells were plated in 96-115 
well plates at a density of 5x103 cells per well and were allowed to grow to 70% confluence. After 24h, 116 
the cells were separated into four treatment groups and treated with different concentrations of SSd 117 
(2.5, 5.0, 10.0, 15.0 μg/ml) respectively. After 24，48, and 72 h incubation, freshly prepared MTT test 118 
solution, was added to each well. After a 4h incubation period, the supernatant was discarded and 150μl 119 
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DMSO was added to dissolve the crystals. All analyzes were performed in biological triplicates. The 120 
absorbance was measured using an ELISA reader at a wavelength of 490 nm. The proliferation 121 
inhibition rate (PIR%) was calculated using the formula: (PIR%)=(control well A490-experimental 122 
well A490)/ control well A490 x 100%. 123 
2.5 Apoptosis assay 124 
Apoptosis analysis of both SMMC-7721 and HepG2 cells was conducted using the Annexin V-FITC 125 
Apoptosis Detection Kit according to the manufacturer's instructions (Invitrogen, CA, USA). Briefly, 126 
cells (2×106 cells/dish) were seeded into six-well plates. Following 24h treatment with and without 127 
SSd (5.0mg/ml), cells were removed from the plates using trypsin, washed with ice-cold PBS twice, 128 
and harvested. The cells were then resuspended to approximately 1×106 cells/ml and stained with 129 
Annexin V-APC and propidium iodine according to the manufacturer’s instructions (KeyGEN 130 
BioTECH). Annexin V-APC/PI binding was analyzed by flow-cytometry using a BD FACSCalibur 131 
system. Each histogram was constructed with the data from at least 5000 events. All the samples were 132 
analyzed in triplicate. 133 
2.6 Immunocytochemistry 134 
Immunocytochemical staining was performed to assess the expression of COX-2, p-STAT3 and 135 
STAT3 proteins in SMMC-7721 cells. Cells were plated on coverslips in 24-well cell culture plates at 136 
a cell density of 10x104 cells/well. When the cells reached 60-70% confluency they were separated 137 
into different treatment groups. The staining was performed on the coverslips obtained from each of 138 
the treatment groups. Immunocytochemistry S-P (Streptavidin/Peroxidase) methods were used 139 
according to the manufacturer’s instructions. Briefly, the slides were placed into 0.1% Triton-X 100 140 
for 5 min and incubated for 15 minutes in 3% hydrogen peroxide at room temperature. After washing 141 
with PBS (pH 7.4), the slides were blocked by blocking reagent (normal goat serum) for 15 min at 142 
room temperature. The slides were incubated with primary antibody (rabbit anti human) at 4°C 143 
overnight in a humidity chamber. Slides were washed with PBS and then incubated with goat 144 
biotinylated anti rabbit immunoglobulin G for 10 min and then incubated with streptavidin/horseradish 145 
peroxidase for 10 min at 37°C. Finally, the slides were incubated with DAB working solution (Tiangen, 146 
China) for 5 min and counterstained with hematoxylin (nuclear counterstain) after they were washed 147 
with PBS. As a negative control, sections were treated with PBS with the omission of the primary 148 
antibody. 149 
The images were quantitatively analysed using ImagePro Plus 7.1 software (Media Cybernetics, Silver 150 
Spring, MD) as described in previous studies (37, 38). The threshold for positive staining was defined 151 
by a pathologist who was blinded to the treatment. This threshold was used to analyse all of the 152 
subsequent samples. The results, which represent the average positive staining above the threshold for 153 
individual sections, were expressed as image units. The mean of these values represents the amount of 154 
staining per treatment group used for subsequent statistical comparison. The reading from the control 155 
group was set to 1 and the values for the others were derived from actual readings divided by the control 156 
reading. 157 
2.7 Western blotting analysis.  158 
Both SMMC-7721 and HepG2 cells were seeded into 6-well plates (2.5×105/well). After 24 h the cells 159 
were divided into different groups and treated with vehicle (Control group), or IL-6 (25ng/ml) only, or 160 
IL-6 +SSd (2.5, 5.0, 10.0 µl/ml), orIL-6+AG90 (10, 50, 100µmol/L), by adding the indicated drug 161 
concentrations directly into the cell culture medium. The next day tumor cells were lysed in lysis buffer 162 
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and centrifuged at 12 000 g for 15 min. Protein concentrations were determined using a Pierce™ BCA 163 
Protein Assay Kit (Thermo Fisher Scientific) following the manufacturer’s instructions. The protein 164 
was separated by 10% SDS polyacrylamide gel electrophoresis and then transferred to a polyvinylidene 165 
fluoride membrane. After blocking for 1 h with 5% milk in tris-buffered saline and tween 20, the 166 
primary antibodies [total STAT3 (1:200), p-tyr-705 STAT3 (1:1000), C/EBPβ (1:1000), COX-2 167 
(1:1000), and β-actin (1:300)] were added and incubated at 4˚C overnight. After incubation with 168 
secondary antibodies, horseradish peroxidase-conjugated secondary antibody (1:3000), membranes 169 
were visualized with ECL (Santa Cruz, CA) detection. Protein bands were scanned using Odyssey 170 
bands scanner (S/N ODY-2792 model: 9120). The intensities of the bands were analyzed using 171 
Bandscan Software.  172 
2.8 Quantitative reverse transcriptase-PCR (qRT-PCR). 173 
QRT-PCR was conducted to assess the expression of mRNA for COX-2, STAT3, C/EBPβ in both 174 
SMMC-7721 and HepG2 cells after treatment with SSd at various concentrations, or addition of 175 
AG490. Cells were first seeded into 6cm dishes (2×106 cells/dish). After 24h incubation, cells in 176 
treatment groups (Group 2 to 5) were then treated with IL-6 at 25ng/ml plus SSd (0, 2.5. 5.0 and 10.0 177 
µg/ml), or JAK2 kinase inhibitor AG490 (0, 10, 50 and 100 µmol/L), for a further 24h. The total RNA 178 
in cells in all treatment groups was extracted using TRIzol reagent (Invitrogen, CA, USA). RNA 179 
integrity was confirmed by absorption at 260 nm and 280 nm using a spectrophotometer (Beckman 180 
Coulter Du® 800, CA, USA). cDNA was synthesized using Transcript High Fidelity cDNA Synthesis 181 
Kit (Fermentas). The primer sequences for target genes of COX-2, STAT3, C/EBPβ and β-actin are 182 
detailed in Table 1. Using the Light Cycler 480 SYBR Green I Master Mix (Roche), qRT-PCR was 183 
performed according to the qRT-PCR manufacturer’s protocol (Invitrogen, CA, USA). Melting curve 184 
detection was used to analyze the specificity of qRT-PCR products. The expression of mRNAs were 185 
analyzed by Mx Pro QPCR software version 3.0, and the housekeeping gene, β-actin, was used as an 186 
internal control to normalize variations in the integrity and total amount of cDNA. Data are expressed 187 
as relative expression as described by Livak and Schmittgen (39). 188 
Table 1 Primers used for RT-qPCR 189 
Target gene Forward primer (5’→3’) Reverse primer (5’→3’) 
COX-2 AGTATCACAGGCTTCCATTGACCAG CCACAGCATCGATGTCACCATAG 
STAT3 GGCTTCTCCTTCTGGGTCTGG TCTTACCGCTGATGTCCTTCTCC 
C/EBPβ GTTCATGCAACGCCTGGTG AAGCAGTCCGCCTCGTAGTAGAAG 
β-actin ATCGTGCGTGACATTAAGGAGAAG AGGAAGGAAGGCTGGAAGAGTG 
2.9 Luciferase reporter assay 190 
Bioinformatic analysis (JASPAR (http://jaspar.genereg.net/) was used to predict binding sites between 191 
transcription factors and gene promoters. HepG2 cells seeded in 96-well plates were cultured for 24h 192 
reaching 60-80 % confluency before transfection. The luciferase reporter vector, the wild-type (WT) 193 
or mutant (Mut) (GeneChem, China) together with pcDNA3.1 plasmid (GeneChem, China) were co-194 
transfected using the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). At 48h post-transfection, 195 
the Dual Luciferase Assay Kit (Promega) was used to examine the luciferase activity according to the 196 
manufacturer's instructions. Renilla luciferase activity was used as a control. 197 
2.10 Cell transfection assay 198 
All the small interfering RNA (siRNA) sequences targeting STAT3 (Genepharma, Shanghai, China) 199 
have been listed in Table 2. STAT3 knockdown was performed by transfecting STAT3-siRNA#1-3. 200 
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Transfection assays were conducted when the cells reached approximately 60-80% confluency 201 
according to the manufacturer’s instructions. Lipofectamine 2000 (Invitrogen, USA), Total RNA from 202 
cells was extracted 48h post-transfection. 203 
Table 2. siRNA Sequences used in the present study 204 
Genes sense（5'-3'） antisense（5'-3'） 
STAT3-siRNA1-398 CCACUUUGGUGUUUCAUAATT UUAUGAAACACCAAAGUGGTT 
STAT3-siRNA2-978 GCAACAGAUUGCCUGCAUUTT AAUGCAGGCAAUCUGUUGCTT 
STAT3-siRNA3-1070 CCCGUCAACAAAUUAAGAATT UUCUUAAUUUGUUGACGGGTT 
 205 
2.11 Statistical analysis 206 
All statistical analysis was performed using SPSS package version 24.0. The results were expressed as 207 
means ±SD as indicated. All treatments were arranged in a randomized block design with three 208 
replicates. Analysis of variance was used for comparison among different treatment groups. The 209 
difference was considered statistically significant when P<0.05. 210 
3 Results 211 
3.1 Inhibitory effect of SSd on cancer cell proliferation  212 
The SSd antiproliferative effects in human hepatocellular carcinoma cancer cell lines, SMMC-7721 213 
and HepG2, were demonstrated in a dose- and time-dependent manner using the MTT proliferation 214 
assay. As illustrated in Fig. 1, the degree of inhibition was concomitant with an increase in SSd dosage 215 
and the significance (P>0.05) was demonstrated in all treatment groups compared to control (vehicle).  216 
3.2 SSd induced apoptosis 217 
The degree of apoptosis was analyzed by flow cytometry in all treatment groups and compared to the 218 
control groups in both SMMC-7721 and HepG2 cells (Fig. 2A). Post 24 h treatment with SSd, the 219 
percentages of apoptotic cells were significantly increased in both cell types in a dose-dependent 220 
fashion compared to controls (P<0.05 or 0.01) (Fig. 2B). At the protein level, SSd treatment also 221 
resulted in an increase in the pro-apoptotic protein Bax and a decrease in the anti-apoptotic protein 222 
Bcl-2. The high expression of CDK6 (a key protein kinase, which activates cell proliferation) and 223 
cyclin B1 were inhibited by SSd in both SMMC-7721 and HepG2 cells (Fig. 2C). 224 
3.3 SSd suppressed protein expression of p-STAT3 and COX-2   225 
We utilized immunohistochemical staining to determine the expression and localization of STAT3, p-226 
Stat3 and COX-2 in tumor cells. Total STAT3, COX2 and p-tyr-705 STAT3 strongly stained in the 227 
nuclear compartment (brown staining) in the control groups. Immunocytochemistry quantitation, using 228 
ImagePro Plus 7.1 software, showed  significant increase in p-tyr-705 STAT3 and COX-2 when the 229 
cells were exposed to IL-6, however no significant changes were observed in total STAT3 with IL6 230 
treatment. Both AG490 and SSd effectively inhibited the expression of p-tyr-705 STAT3 and COX-2 231 
(Fig. 3A and B). However, the expression of total STAT3 showed no difference between the control 232 
group and the SSd group (Fig. 3A and B).  Both AG490 and SSd effectively inhibited the expression 233 
of p-tyr-705 STAT3 and COX-2 (Fig. 3A and B). However, the expression of total STAT3 showed no 234 
difference between the control group and the SSd group (Fig. 3A and B). The inhibition of p-STAT3 235 
and COX-2 expression by both SSd (5μg/ml) and AG490 (25μmol/L) was statistically significant 236 
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(p<0.01). Interestingly, whilst treatments with AG490 and SSd significantly decreased nuclear COX2, 237 
a slight increase in COX2 expression was present in the cytoplasmic compartment. 238 
3.4 SSd Inhibited p-STAT3, C/EBPβ and COX-2 protein 239 
STAT3 and C/EBPβ are key signaling molecules involved in carcinogenesis of HCC. Here we 240 
determined the effects of SSd on the activation of STAT3 by measuring the level of p-STAT3 (tyr 705) 241 
in the total protein extracts. It is well known that the transcription factor CCAAT/enhancer-binding 242 
protein (C/EBPβ) plays a key role in regulating COX-2 gene expression (40, 41). Therefore, we 243 
determined whether C/EBPβ was also an important target for SSd in these tumor cells. The 244 
representative images of Western blotting results from all treatment groups are presented in Figs. 4 & 245 
5. As shown in Figs. 4 & 5, IT-6 (25ng/mL) treatment resulted in nuclear translocation and 246 
phosphorylation of STAT3 in both cell types. The protein expression of C/EBPβ, p-tyr-705 STAT3 247 
and COX-2 were significantly higher compared to untreated cells (P<0.01). Following the addition of 248 
SSd at various concentrations in cell culture, the protein expression of all C/EBP-β, p-tyr-705 STAT3 249 
and COX-2 were significantly inhibited (P<0.01) in both SMMC-7721 and HepG2 cells and the 250 
inhibition was demonstrated in a dose-dependent manner (Fig 4). The observed inhibition of protein 251 
expression of C/EBPβ, p-tyr-705 STAT3 and COX-2 by AG490 (Fig 5) was similar to that 252 
demonstrated by SSd. The protein level of total STAT3 did not vary significantly among the five 253 
treatment groups. 254 
3.5 Effects of SSd on the expression of mRNA for STAT3, C/EBPβ and COX-2 255 
The mRNA expression of the target genes in the tumor cells were analyzed by qRT-PCR. The 256 
expression of mRNA for COX-2 and C/EBPβ was significantly higher in the IL-6 treated group 257 
compared to the control group (P<0.01) (shown in Fig. 6). However, the increased mRNA expression 258 
was abrogated by SSd and AG490 and the inhibition was observed in a dose-dependent manner. When 259 
compared with cells treated with IL-6, the mRNA expression for both COX-2 and C/EBPβ was 260 
significantly abrogated by both SSd and Ag490 (P<0.05 and 0.01) and the observed inhibition by SSd 261 
was similar to that observed by AG490 treatment. STAT3 expression showed no significant difference 262 
in all treatment groups tested. 263 
3.6 STAT3/C/EBPβ signaling pathway regulated the expression of COX2 in HCC cells 264 
In order to verify the regulatory mechanisms of STAT3/C/EBPβ/COX2 signaling pathway, we used 265 
the JASPAR program to predict the binding sites between these genes. The results suggested that 266 
STAT3 has a potential binding site on the C/EBPβ promoter, in addition, C/EBPβ has a potential 267 
binding site on the COX2 promoter. To verify the validity of the binding sites between genes, the 268 
luciferase reporter vectors were constructed for C/EBPβ and COX2 promoters (Fig.7 A, B). The 269 
luciferase reporter assay results showed co-transfection of cells with C/EBPβ-WT vector and 270 
pcDNA3.1-STAT3 significantly increased luciferase reporter activity, however, C/EBPβ-Mut in 271 
STAT3's putative targeting sites did not result in these effects (Fig. 7B). Similarly, co-transfection of 272 
cells with COX2-WT vector and pcDNA3.1-C/EBPβ significantly increased luciferase reporter 273 
activity, however, COX2-Mut in C/EBPβ's putative targeting sites did not result in these effects (Fig. 274 
7D). In order to investigate the regulation of STAT3 on C/EBPβ and COX2 expression, three STAT3-275 
specific small interfering RNAs (siRNA1-3) and a negative control (siRNA-NC) were transfected into 276 
HepG2 and SMMC-7721 cells to evaluate the inhibition efficiency of STAT3. As shown in Figure 7E, 277 
STAT3-siRNA1-3 produced the greatest reduction in endogenous STAT3 expression. Meanwhile, 278 
compared with the control group, interfering with the expression of STAT3 significantly down-279 
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regulated the mRNA levels of C/EBP β and COX2 (Fig. 7 F, G). These results suggest that 280 
STAT3/C/EBPβ signaling positively regulates the expression of COX2 in HCC. 281 
 282 
4 Discussion 283 
Building on our previous work, which identified the significant role of SSd in COX2 suppression in 284 
hepatocarcinoginesis and its chemo-preventative effects in HCC (13, 14, 34, 35), in this report, we 285 
extended our study to show that anti-tumorigenic effects of SSd acts through the intermediatory p-286 
STAT3/C/EBPβ signaling pathway to suppress COX-2. SSd effectively inhibited cell proliferation in 287 
a dose-dependent manner via regulating apoptosis. Most importantly, we provided evidence to 288 
support the signaling pathway from STAT3 to C/EBPβ, and then to COX2, leading to COX2 289 
suppression by SSd, uncovering the upstream regulatory pathway of COX2. This represents a novel 290 
mechanism of action for SSd. 291 
Overexpression of COX-2 has been previously reported to induce tumor initiation, progression and 292 
angiogenesis in solid tumors, including liver cancers (24-26, 28, 29), identifying anti-COX-2 293 
treatment as an important target for liver cancer. Selective COX-2 inhibitors have demonstrated a 294 
significant inhibition on the proliferation of HCC cells (42). The commercially available celecoxib, a 295 
selective nonsteroidal anti-inflammatory drug (NSAID) COX-2 inhibitor, has been shown to exert its 296 
anticarcinogenic effect in the liver and in liver cell lines by inducing apoptosis through the intrinsic 297 
apoptotic pathway (42). Treatment of cancer cells with celecoxib led to demonstrated alterations in 298 
the relative levels of the Bcl-2 family, pro-apoptotic proteins increased and anti-apoptotic proteins 299 
decreased (43, 44). In keeping with these observations, we demonstrated that the natural product SSd 300 
significantly suppressed COX-2 protein and mRNA levels (Figs. 4 and 6). These findings were 301 
accompanied by significant inhibition of cell proliferation in both SMMC-7721 and HepG2 cells in a 302 
dose-and time-dependent manner. The magnitude of inhibition in both cell lines were similar (Fig. 1). 303 
We further demonstrated that SSd exerted its anti-carcinogenic effect in these cancer cell lines by 304 
decreasing the antiapoptotic protein Bcl-2 and increasing the pro-apoptotic protein Bad (Fig. 2). The 305 
antitumorigenic effects of SSd observed have similar properties to celecoxib treatment, suggesting 306 
that pro-apoptosis in our study may be initiated through COX-2 inhibition. 307 
There is considerable information on the downstream regulatory network of COX-2 overexpression 308 
linking elevated COX-2 expression to carcinogenesis. COX-2 overexpression has been reported to 309 
enhance the expression of key oncogenic genes, (HB-EGF, Krt23, Pak1 and TNFRSF12A) and 310 
signaling cascades (AKT, STK33 and MTOR pathway), which contribute to the initiation and 311 
progression of HCC formation (24). To-date no study showing how SSd exerts its COX-2 suppression 312 
through the upstream regulatory network has been reported. This report described a novel antitumor 313 
action of SSd by inhibition of specific intermediatory upstream regulators of COX-2 in HCC. 314 
To elucidate the mechanism by which SSd inhibits COX-2 expression, we analyzed the protein 315 
expression of STAT3, p-STAT, C/EBPβ and COX-2 and mRNA expression for STAT3, C/EBPβ and 316 
COX-2 genes after treatment with SSd at increasing dosage concentrations. We found that at low 317 
concentrations, between 2.5-10 µg/ml, SSd effectively suppressed both mRNA and protein expression 318 
of C/EBPβ and COX-2 (Figs. 4 and 6). IL-6 effectively stimulated the expression of C/EBPβ and COX-319 
2 and significantly activated STAT3. Considering SSd suppressed the phosphorylation of STAT3 320 
(active form of STAT3), and AG490 exhibited a similar inhibitory profile to that of SSd on STAT3, p-321 
STAT, C/EBPβ and COX-2, our results suggested a direct association between SSd-induced inhibition 322 
of COX-2 with downregulation of C/EBPβ. Furthermore, we used the JASPAR program to predict the 323 
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binding sites between STAT3, C/EBPβ and COX2 genes, and revealed that STAT3 has a potential 324 
binding site on the C/EBPβ promoter, and C/EBPβ has a potential binding site on the COX2 promoter. 325 
The luciferase reporter assay was used to validate the binding sites between genes in HCC cells. The 326 
results suggested that STAT3/C/EBPβ signaling positively regulates the expression of COX2 in HCC 327 
cells, providing evidence of the signaling pathway from STAT3 to C/EBPβ, and then to COX2. 328 
In agreement with our data, previous studies demonstrated that the transcription factor C/EBPβ, as an 329 
upstream regulator of the COX-2 gene, was significantly elevated in various cancer tissues such as 330 
colorectal cancer, human ovarian epithelial tumor, gastric carcinoma (45), prostate cancer (46) and 331 
human HCC (13). Thus, further confirming an active role for C/EBPβ in tumorigenesis and cancer 332 
development.  Other studies have found that the activation of C/EBPβ is crucial for the initial induction 333 
of COX-2 by growth factors, tumor promoters, cytokines and other inflammatory mediators in various 334 
cell types (41, 47), supporting suppression of this pathway, as demonstrated by SSd may be an 335 
important anti-cancer therapy. Overlapping overexpression of C/EBPβ and COX-2 has been observed 336 
in gastric carcinomas suggesting that C/EBPβ has the potential to mediate gastric carcinogenesis via 337 
the regulation of COX-2 expression (45). In human prostate tissues, high correlation of C/EBPβ and 338 
COX-2 expression were associated with chronic inflammation and prostate cancer development (46). 339 
Furthermore, anti-inflammatory drugs, such as salicylate, suppressed COX-2 expression via inhibition 340 
of C/EBPβ binding to the COX-2 promoter (48). Our previous study demonstrated a correlation 341 
between C/EBPβ overexpression and COX-2 overexpression in human HCC tissue (34). Collectively, 342 
these studies provide further support for our present findings, which show activation of the C/EBPβ 343 
and COX-2 pathway plays a vital role in carcinogenesis. 344 
In conclusion, our study demonstrates that the antitumorigenic effects of SSd on HCC cells is a 345 
consequence of the suppression of COX-2 expression, which is mediated by downregulation of p-346 
STAT3 via C/EBPβ. Mechanistically this study supports that SSd blocks phosphorylation and nuclear 347 
translocation of STAT3, then suppresses the expression of C/EBPβ mRNA and protein, leading to the 348 
inhibition of COX-2 expression. Linking STAT3, C/EBPβ and COX-2, this report presents a novel 349 
mechanism of action for SSd and advances our understanding of the pharmacological action of SSd in 350 
anti-tumorigenicity. Our results also suggests that low doses of SSd, a natural compound extract, shows 351 
great potential as a novel alternative chemo-preventive agent for the treatment of HCC.  352 
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 493 
FIGURE LEGENDS 494 
Figure 1. SSd inhibited proliferation of SMMC-7721 and HepG2 cells. Adherent liver cancer 495 
cells (SMMC-7721 and HepH2) were seeded in 96-well plates (5x103cells/well) and incubated with 496 
different concentrations of SSd ranging from 2.5µg to15µg/ml, and time intervals ranging from 24-497 
72h, as indicated on the histograms. Cell proliferation was determined by the MTT assay. Data were 498 
expressed as mean ± SD. 499 
Figure 2. SSd increased apoptosis in SMMC-7721 and HepG2 cells. A: The tumor cells were 500 
treated with SSd at various concentrations or vehicle (control) and analyzed by flow cytometric 501 
analysis. B: Apoptosis rates in all treatment groups are presented as a histogram (data were expressed 502 
as mean ± SD). C: Western blots of Bax (a pro-apoptotic protein), CDK6, Bcl-2 and cyclin B1. β-503 
actin was used as a loading control. 504 
Figure 3: Alteration of p-STAT3, COX-2 and STAT3 expression post treatment with SSd.  A: 505 
Representative images of immunocytochemical staining of SMMC-7721 cells pre- and post-506 
treatment with AG490, SSd and IL-6. Control group: cells treated with PBS; IL-6 Group: Cells 507 
treated with IL-6 (25ng/ml); AG90 Group: Cells treated with IL-6 (25ng/ml) + AG490 (25 μmol/L) 508 
and SSd Group: Cells treated with IL-6 (25ng/ml) + SSd (5μg/ml).  (DAB used as chromogen; 509 
original magnification x 200): nuclear immunoreactivity.  B: Results from quantitative analysis of 510 
images using ImagePro Plus 7.1 software and data were expressed as arbitrary image units. **p < 511 
0.01, *p < 0.05 compared to the control. Nucleus was stained using hematoxylin (blue), antibody 512 
staining (brown).  513 
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Figure 4. Protein expression of total STAT3, p-STAT3, C/EBPβ and COX-2 following 514 
treatment with SSd. SMMC-7721 and HepG2 cells were seeded into 6-well plates (2.5×105/well). 515 
After 24 h culture in RPMI-1640 medium, the cells were divided into 5 groups and treated with SSd 516 
in the following conditions:  1) Control group cells received no drug treatment；2) cells treated with 517 
IL-6 (25 ng/ml) only; 3) cells treated with IL-6 (25 ng/ml) + SSd (2.5 μg/ml); 4) cells treated with IL-518 
6 (25 ng/ml) + SSd (5.0 μg/ml); 5) cells treated with IL-6 (25 ng/ml) + SSd (10.0 μg/ml). 519 
Representative Western blot of results are shown in upper panels. For the quantitation of Western 520 
blots, protein expression was normalized to β-actin levels in each lane and expressed relative to 521 
levels in normal cells. The data are presented as the mean ±SD of three separate experiments. 522 
*indicated P< 0.05 and **meant P< 0.01 when compared with group 2 where cells were treated with 523 
IL-6 only. 524 
Figure 5. Protein expression of total STAT3, p-tyr-705 STAT3, C/EBPβ and COX-2 following 525 
treatment with AG490 (JAK2 inhibitor).  Cell culture conditions are as described in Fig. 4. Tumor 526 
cells (HepG2 and SMMC-7721) were divided into different groups and treated with different 527 
concentrations of AG490 as follows: 1) control group- cells received no drug treatment；2) cells 528 
treated with IL-6 (25 ng/ml) only; 3) cells treated with IL-6 (25 ng/ml) + AG490 (10μmol/L); 4) cells 529 
treated with IL-6 (25 ng/ml) + AG490 (50μmol/L); 5) cells treated with IL-6 (25 ng/ml) + AG490 530 
(100μmol/L). 531 
Figure 6. Expression of mRNA for total STAT3, C/EBP β and COX-2 as determined by qRT-532 
PCR.  A: SSd treated cells-upper panel:  Tumor cells (HepG2 and SMMC-7721) were divided into 533 
5 groups and treated with different concentrations of SSd as follows: 1) control group-cells received 534 
no drug treatment；2) cells treated with IL-6 (25 ng/ml) only; 3) cells treated with IL-6 (25 ng/ml) + 535 
SSd (2.5 μg/ml); 4) cells treated with IL-6 (25 ng/ml) + SSd (5.0 μg/ml); 5) cells treated with IL-6 536 
(25 ng/ml) + SSd (10.0 μg/ml). B: AG490 treated cells-lower panel: Both HepG2 and SMMC-7721 537 
cells were divided into identical 5 groups and treated AG490 as various concentrations as follows: 1) 538 
control group- cells received no drug treatment；2) cells treated with IL-6 (25 ng/ml) only; 3) cells 539 
treated with IL-6 (25 ng/ml) + AG490 (10μmol/L); 4) cells treated with IL-6 (25 ng/ml) + AG490 540 
(50μmol/L); 5) cells treated with IL-6 (25 ng/ml) + AG490 (100μmol/L). Data are expressed as 541 
relative expression using the ΔΔCq method. **P < 0.01 and *P < 0.05 compared with group 2 (cells 542 
treated with 25ng/mL IL-6).  543 
Figure 7. STAT3/C/EBPβ signal pathway regulate the expression of COX2 in HCC cells. 544 
Schematic illustrating the STAT3 binding sites at the promoter of C/EBP β (A), and the C/EBP β 545 
binding sites at the promoter of COX2 (B). (C) Luciferase reporter assay was applied to verify the 546 
targeted binding effect between STAT3 and C/EBP β, **P<0.01. (D) Luciferase reporter assay was 547 
applied to verify the targeted binding effect between C/EBP β and COX2, **P<0.01. (E) qRT-PCR 548 
analysis of STAT3 expression following transfected HepG2 and SMMC-7721 cells with STAT3-549 
siRNA1-3. *P< 0.05, **P<0.01. (F) qRT-PCR analysis of C/EBP β expression following transfected 550 
HepG2 and SMMC-7721 cells with STAT3-siRNA1-3. *P< 0.05, **P<0.01. (G) qRT-PCR analysis 551 
of COX2 expression following transfected HepG2 and SMMC-7721 cells with STAT3-siRNA1-3. 552 
*P< 0.05, **P<0.01.  553 
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